Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation

The continued shortage of donor organs, together with a sustained increase in the number of potential donors with hepatitis C virus (HCV) infection (related to the ongoing opioid epidemic) and the advent of direct-acting anti-viral agents (DAAs), has led to increased utilization of HCV-positive donors for heart transplantation (HT).1 Furthermore, multiple recent studies have shown that 1-year HT survival using HCV-positive donors in the current era of DAAs is similar to the HT survival using non-HCV donors.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: RESEARCH CORRESPONDENCE Source Type: research